{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:06:56Z","timestamp":1779379616065,"version":"3.53.1"},"reference-count":37,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["DB-2020C2-20306"],"award-info":[{"award-number":["DB-2020C2-20306"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>To assess the within-class variation in kidney outcomes following initiation of sulfonylurea therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Research design and methods<\/jats:title>\n                    <jats:p>We used claims data of enrollees in commercial, Medicare Advantage, and traditional Medicare health plans between 2014 and 2021\u2009to emulate a target trial including adults \u226521 years with type 2 diabetes at moderate cardiovascular risk to compare initiation of glimepiride, glipizide, or glyburide on the incidence of chronic kidney disease (CKD) stage 3 or worse, including initiation of kidney replacement therapy (primary outcome); secondary outcomes examined incident CKD stages 3-4, kidney failure (including kidney replacement therapy), all-cause mortality, and hypoglycemia requiring emergency department or hospital care. Random treatment assignment was emulated using propensity scores, estimated using the super learner ensemble method, and incorporated as inverse probability of treatment weights into proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The weighted study cohort included 295\u2009092 individuals starting glimepiride (n=134\u2009926), glipizide (n=145\u2009984), and glyburide (n=14\u2009182). One year after treatment initiation, stage 3 or worse CKD developed in 2.1% of patients in the glimepiride group, 2.2% in the glipizide group, and 1.8% in the glyburide group. Glyburide was associated with a lower risk of kidney complications compared with both glimepiride (HR 0.84, 95%\u2009CI 0.76 to 0.92)\u2009and glipizide (HR 0.81, 95%\u2009CI 0.73 to 0.89), despite a higher risk of severe hypoglycemia (HR 1.47, 95% CI 1.27 to 1.71\u2009vs glipizide and HR 1.22, 95% CI 1.05 to 1.42 vs glimepiride). In contrast, the risk of kidney complications was modestly increased with glipizide compared with glimepiride use (HR 1.04, 95%\u2009CI 1.00 to 1.07).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Glyburide was associated with a modestly lower risk of kidney complications, despite a higher risk of hypoglycemia, while glipizide was associated with a higher risk of kidney complications. These hypothesis-generating findings suggest important within-class differences that warrant consideration in clinical decision-making and future research. Despite rigorous prespecified causal inference analytic methods, the risk of unmeasured confounding and bias by indication with the use of observational data remains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05214573\">NCT05214573<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjdrc-2025-005775","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:30:27Z","timestamp":1779377427000},"page":"e005775","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of sulfonylureas on kidney outcomes in adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05214573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05214573","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3857-9445","authenticated-orcid":false,"given":"Stacey","family":"Sklepinski","sequence":"first","affiliation":[{"name":"School of Medicine, University of Maryland Baltimore, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-7900","authenticated-orcid":false,"given":"Alexandria A","family":"Ratzki-Leewing","sequence":"additional","affiliation":[{"name":"Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"},{"name":"University of Maryland Institute for Health Computing, North Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sindhu","family":"Swarna","sequence":"additional","affiliation":[{"name":"Mayo Clinic Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Rochester, Minnesota, USA"},{"name":"Optum Labs, Eden Prairie, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[{"name":"Mayo Clinic Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Rochester, Minnesota, USA"},{"name":"Optum Labs, Eden Prairie, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C","family":"Polley","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, The University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J","family":"Neumiller","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Washington State University, Spokane, Washington, USA"},{"name":"Providence Medical Research Center, Spokane, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo J","family":"Galindo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E","family":"Umpierrez","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P","family":"Brito","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-2898","authenticated-orcid":false,"given":"Victor M","family":"Montori","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy M","family":"Mickelson","sequence":"additional","affiliation":[{"name":"Mayo Clinic Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina Grubina","family":"McCoy","sequence":"additional","affiliation":[{"name":"Division of Gerontology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"},{"name":"University of Maryland Institute for Health Computing, North Bethesda, Maryland, USA"},{"name":"Division of Endocrinology, Diabetes, & Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026052108301936000_14.3.e005775.1","unstructured":"Centers for Disease Control and Prevention . National diabetes statistics report. 2024. Available: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html#cdc_report_pub_study_section_8-coexisting-conditions-and-complications [Accessed 17 Aug 2025]."},{"key":"2026052108301936000_14.3.e005775.2","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0085"},{"key":"2026052108301936000_14.3.e005775.3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012070718"},{"key":"2026052108301936000_14.3.e005775.4","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009"},{"key":"2026052108301936000_14.3.e005775.5","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"2026052108301936000_14.3.e005775.6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15196"},{"key":"2026052108301936000_14.3.e005775.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa2032271"},{"key":"2026052108301936000_14.3.e005775.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100852","article-title":"Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes","volume":"3","author":"McCoy","year":"2024","journal-title":"JACC Adv"},{"key":"2026052108301936000_14.3.e005775.9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.444"},{"key":"2026052108301936000_14.3.e005775.10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2215\/CJN.0000000587","article-title":"Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk","volume":"20","author":"Neumiller","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026052108301936000_14.3.e005775.11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-8587(14)70213-X","article-title":"Mortality risk among sulfonylureas: a systematic review and network meta-analysis","volume":"3","author":"Simpson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026052108301936000_14.3.e005775.12","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1789"},{"key":"2026052108301936000_14.3.e005775.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01496.x"},{"key":"2026052108301936000_14.3.e005775.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2025-005646","article-title":"Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation","volume":"14","author":"Sklepinski","year":"2026","journal-title":"BMJ Open Diab Res Care"},{"key":"2026052108301936000_14.3.e005775.15","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2026052108301936000_14.3.e005775.16","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2014.0038"},{"key":"2026052108301936000_14.3.e005775.17","unstructured":"Polley E , LeDell E , Kennedy C , et al . SuperLearner: super learner prediction. 2021. Available: https:\/\/CRAN.R-project.org\/package=SuperLearner [Accessed 04 Oct 2023]."},{"key":"2026052108301936000_14.3.e005775.18","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner","volume":"6","author":"van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"key":"2026052108301936000_14.3.e005775.19","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000627"},{"key":"2026052108301936000_14.3.e005775.20","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515"},{"key":"2026052108301936000_14.3.e005775.21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7297"},{"key":"2026052108301936000_14.3.e005775.22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9681"},{"key":"2026052108301936000_14.3.e005775.23","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1214\/20-EJS1740","article-title":"Correcting an estimator of a multivariate monotone function with isotonic regression","volume":"14","author":"Westling","year":"2020","journal-title":"Electron J Stat"},{"key":"2026052108301936000_14.3.e005775.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.96867"},{"key":"2026052108301936000_14.3.e005775.25","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d61eeb"},{"key":"2026052108301936000_14.3.e005775.26","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.2337\/dc22-0348","article-title":"Trends in All-Cause and Cause-Specific Mortality Among Individuals With Diabetes Before and During the COVID-19 Pandemic in the U.S","volume":"45","author":"Kim","year":"2022","journal-title":"Diabetes Care"},{"key":"2026052108301936000_14.3.e005775.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-015-0204-5","article-title":"Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors","volume":"14","author":"Cea Soriano","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2026052108301936000_14.3.e005775.28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.23067","article-title":"Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors","volume":"8","author":"Turchin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026052108301936000_14.3.e005775.29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/VHRM.S33194","article-title":"Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]","volume":"8","author":"Basit","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"2026052108301936000_14.3.e005775.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1143-3"},{"key":"2026052108301936000_14.3.e005775.31","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4337"},{"key":"2026052108301936000_14.3.e005775.32","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.imbio.2019.08.008","article-title":"NLRP3 inflammasome inhibitor glyburide expedites diabetic-induced impaired fracture healing","volume":"224","author":"Yang","year":"2019","journal-title":"Immunobiology"},{"key":"2026052108301936000_14.3.e005775.33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s44161-024-00453-9","article-title":"Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk","volume":"3","author":"McCoy","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"2026052108301936000_14.3.e005775.34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.oret.2024.05.003","article-title":"Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy","volume":"8","author":"Barkmeier","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"2026052108301936000_14.3.e005775.35","doi-asserted-by":"crossref","unstructured":"McCoy RG , Swarna KS , Polley EC , et al . Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial. Endocr Pract 2026. doi:10.1016\/j.eprac.2026.01.012","DOI":"10.1016\/j.eprac.2026.01.012"},{"key":"2026052108301936000_14.3.e005775.36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026052108301936000_14.3.e005775.37","first-page":"2009","article-title":"Trends in Use of Sulfonylurea Types Among US Adults with Diabetes: NHANES 1999-2020","volume":"38","author":"Shin","year":"2023","journal-title":"J Gen Intern Med"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2025-005775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:30:30Z","timestamp":1779377430000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2025-005775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjdrc-2025-005775"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2025-005775","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}